This paradoxical outcome suggests a potential immunological conflict between active NMOSD and glioblastoma progression, reinforcing the notion that AQP4-targeted autoimmunity could inherently oppose glioma advancement. This evidence concerns the gene AQP4 and central nervous system cancer.